文献速递前列腺癌

术前68Ga-PSMA PET/CT可识别根治性前列腺切除术后短期预后良好的高危前列腺癌亚组

Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-03-31

该回顾性研究纳入149例未接受新辅助或辅助治疗的高危前列腺癌患者,术前68Ga-PSMA PET/CT显示淋巴结阳性者19例(13%)。PET阴性淋巴结患者PSA持续率低于阳性者(15% vs. 84%,p < 0.001),且PET阴性者1年和2年生化复发无生存率分别为87%和76%。

要点

  • 术前68Ga-PSMA PET/CT淋巴结阳性与高危前列腺癌根治术后PSA持续风险显著升高相关。
  • PET阴性淋巴结患者短期生化复发无生存率较好,1年87%、2年76%。
  • 影像阳性淋巴结和临床T2c-T3分期是多变量分析中PSA持续的独立预测因素。

核心结论

  • 术前68Ga-PSMA PET/CT可能识别出根治性前列腺切除术后未接受辅助治疗即获得良好短期肿瘤学结局的高危前列腺癌亚组。

研究设计与样本

  • 回顾性研究纳入149例高危局限性或局部区域前列腺癌患者,2015年至2020年术前接受68Ga-PSMA PET/CT并行根治性前列腺切除术。
  • 所有患者均未接受新辅助或辅助治疗,研究终点为PSA持续和生化复发。

主要发现

  • 149例中19例(13%)术前68Ga-PSMA PET/CT发现淋巴结受累。
  • 68Ga-PSMA PET/CT识别病理淋巴结受累的敏感性、特异性和准确性分别为68%、95%和92%。
  • PET阴性淋巴结患者PSA持续率低于PET阳性者(15% vs. 84%,p < 0.001)。
  • 多变量分析中,影像阳性淋巴结(OR = 41.03,p < 0.001)和临床T2c-T3分期(OR = 6.96,p = 0.002)与PSA持续相关。
  • PET阴性淋巴结患者1年和2年生化复发无生存率分别为87%和76%。

临床怎么用

  • 术前68Ga-PSMA PET/CT可用于高危前列腺癌术前 staging,帮助识别根治术后短期预后较好的亚组。
  • PET淋巴结阳性患者PSA持续风险高,可能需要更密切的术后监测或个体化辅助治疗决策。

局限性

  • 回顾性研究设计。
  • 短期随访,长期结局尚待未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-risk prostate cancer is associated with adverse pathology and unfavorable outcomes after radical prostatectomy. 68Ga-PSMA PET/CT is more accurate than conventional imaging for preoperative staging. We aimed to evaluate whether lymph node involvement on 68Ga-PSMA PET/CT prior to radical prostatectomy in patients with high-risk prostate cancer is associated with worse short-term oncologic outcomes. METHODS: We retrospectively reviewed 149 patients with high-risk localized or locoregional prostate cancer who underwent 68Ga-PSMA PET/CT prior to radical prostatectomy between 2015 and 2020. None of the patients received neoadjuvant or adjuvant treatment. The study endpoints were PSA persistence and biochemical recurrence. Logistic regression models were used to identify preoperative predictors of PSA persistence. Kaplan-Meier analyses were used to estimate biochemical recurrence-free survival. RESULTS: Of 149 identified patients, 19 (13%) were found to have lymph node involvement on preoperative 68Ga-PSMA PET/CT. The sensitivity, specificity, and accuracy of 68Ga-PSMA PET/CT for identifying pathologic lymph node involvement were 68%, 95%, and 92%, respectively. PSA persistence rate was lower among patients with PET-negative lymph nodes than those with PET-positive nodes (15 vs. 84%, p < 0.001). Positive nodes on imaging (OR = 41.03, p < 0.001) and clinical T2c-T3 stage (OR = 6.96, p = 0.002) were associated with PSA persistence on multivariable analysis. Among patients with PET-negative nodes the 1- and 2-year biochemical recurrence-free survival rates were 87% and 76%, respectively. CONCLUSIONS: Preoperative staging with 68Ga-PSMA PET/CT may identify a subgroup of high-risk prostate cancer patients with favorable short-term outcomes after radical prostatectomy without adjuvant treatment. Future studies will evaluate whether these results are sustained during long-term follow-up.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dekalo S, Kuten J, Mintz I, et al. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer Prostatic Dis. 2021. PMID: 33790418. doi:10.1038/s41391-021-00347-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。